Is TVRD or URGN more undervalued in 2026?

CirclFi compares Tvardi Therapeutics, Inc. (TVRD) and UroGen Pharma Ltd. (URGN) using 13 institutional-grade valuation models. TVRD has a Quality of Company score of 4.1/10 while URGN scores 6.5/10.

Which is a better buy — TVRD or URGN?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do TVRD and URGN valuations compare?

TVRD at $3.49 and URGN at $28.69 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

TVRD vs URGN Valuation Comparison 2026 — Intrinsic Value Analysis

TVRD

Biotechnology

Tvardi Therapeutics, Inc.

Quality

4.1

out of 10

Value Trap

LOW

Price

$3.49

Last close

Models

7/13

Active

URGN

Biotechnology

UroGen Pharma Ltd.

Quality

6.5

out of 10

Value Trap

SAFE

Price

$28.69

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	TVRD Fair Value	TVRD Upside	URGN Fair Value	URGN Upside
Bayesian DCF	Intrinsic	$2.17	-28.9%	$7.27	-74.7%
Earnings Power Value	Intrinsic	—	—	$3.35	-85.4%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$3.04	-3.1%	$14.58	-40.7%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for TVRD vs URGN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

TVRD vs URGN — Which Stock Is More Undervalued?

URGN scores higher with a 6.5/10 quality rating vs TVRD's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Tvardi Therapeutics, Inc. (TVRD) and UroGen Pharma Ltd. (URGN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

TVRD currently trades at $3.49 with a QOC of 4.1/10, while URGN trades at $28.69 with a QOC of 6.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).